Clinical Trial Update: 99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating 99mTc-3PRGD2 SPECT/CT imaging in lung cancer patients is reported with an unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• 99mTc-3PRGD2 SPECT/CT (3PRGD2 radiotracer)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Lung Cancer | EARLY_Phase 1 | Status: UNKNOWN